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hydrolaseAbstract Background: Gene polymorphisms and COPD susceptibility have been paid special
attention and were explored in a large number of studies. The results varied between studies and
populations. We aimed to analyze the relation between susceptibility to COPD and polymorphisms
of Glutathione S-transferases (GST); GSTM1, GSTT1 and Microsomal epoxide hydrolase-1
(EPHX1) genes in a sample of Egyptian population.
Methods: Genetic polymorphisms of GSTM1, GSTT1 and EPHX1 genes in 146 COPD patients
and 130 controls were investigated using multiplex PCR for GSTM1 and GSTT1 genes and PCR-
RFLP for EPHX1 genes.
Results: The frequency of GSTM1-null genotype was higher in patients than in controls (72.6%
versus 43.8%, P< 0.001). Carriers with both null GSTT1 and GSTM1 genes were at a higher risk
of COPD (OR 3.45, 95% CI = 1.07–11.14). The frequency of EPHX1 exon 3 His allele was higher
in patients than controls (19.2% versus 12.7%, P= 0.04). Carriers with exon 3 His allele were at a
higher risk of COPD (OR 1.63, 95% CI = 1.02–2.6, P= 0.04). Carriers with both GSTM1-null
and EPHX1 113Tyr/Tyr or EPHX1 113Tyr/His genotypes were at a higher risk of COPD (OR
3.33, 95% CI = 1.32–8.35 and OR 14.24, 95% CI = 3.02–67.17 respectively). Carriers with both
GSTM1-null and EPHX1 139His/His genotypes were at a higher risk of COPD (OR 5.58, 95%
CI = 2.14–14.52).
Conclusions: EPHX1 exon 3 His allele in addition to the coexistence of other genetic variants,
were signiﬁcant risk factors in susceptibility to COPD in the Egyptian population.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
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Chronic obstructive pulmonary disease (COPD) is character-
ized by the development of airﬂow limitation that is progres-
sive and not fully reversible [1]. In Egypt, the prevalence of
COPD is approximately 1.1% [2]. Cigarette smoking has been
proposed as the most important environmental risk factor in
the development of COPD, however, only a minority of smok-
ers develop clinically symptomatic COPD [3]. These observa-
tions, together with the familial aggregation of COPD [4],
indicate that genetic components contribute to the develop-
ment of COPD [5].
Human Glutathione S-transferases (GSTs) are divided into
three main families: cytosolic, mitochondrial, and membrane-
bound microsomal [6]. The cytosolic GST (cGSTs) superfam-
ily, which exists predominantly in the liver but is also widely
distributed into various tissues, encompasses a number of
isoenzymes. Glutathione is a cytosolic nucleophilic tripeptide
that conjugates epoxides and other reactive intermediates via
GSTs and is used in the prevention of oxidative stress [7].
GSTs alpha (GSTA), mu (GSTM), pi (GSTP), sigma
(GSTS), omega (GSTO), zeta (GSTZ) and theta (GSTT) are
the most ubiquitous isoforms [8]. The GSTM1 and GSTT1
genes are located on chromosomes 1p13 and 22q11.2 respec-
tively. GSTM1 is involved in detoxiﬁcation of active metabo-
lites of polycyclic aromatic hydrocarbons [9]. GSTT1
participates in detoxiﬁcation of small hydrocarbons of tobacco
smoke (such as mono halomethanes and ethylene oxide) [10].
Generally, the homozygous null genotype of GSTM1 is more
frequent than the GSTT1-null genotype [11,12].
Microsomal epoxide hydrolase-1 (EPHX1) plays an impor-
tant role in the metabolism of highly reactive epoxide interme-
diates formed in cigarette smoke. Among 11 polymorphic loci
found in human EPHX1, two genetic polymorphisms have
been reported within the coding region of the EPHX1 gene:
the TAC to CAC transition in exon 3, which changes tyrosine
(Tyr) residue 113 to histidine (His), and the CAT to CGT tran-
sition in exon 4, which changes His residue 139 to arginine
(Arg) [13]. In vitro, cDNA expression studies indicate that
EPHX1 enzymatic activity is decreased by approximately
50% in subjects with the His 113 allele (slow allele) and is
increased by at least 25% in subjects with the Arg 139 allele
(fast allele) [13]. The rare occurrence of both mutations
together produces an enzyme with normal activity. Based on
the polymorphism of EPHX1, the population can be classiﬁed
into four groups of putative EPHX1 phenotypes: normal, fast,
slow and very slow enzyme activity [13,14]. The difference in
frequencies of genotypes might be relevant to different metab-
olizing enzyme activities and types of dominant functional
enzymes against oxidative stress in different races [15]. The
association between the genotypes and COPD susceptibility
varied among different populations. Prevention and early
intervention could be enhanced by data on genetically suscep-
tible individuals. Also, the elucidation of genetic factors and
their association with environmental inﬂuences might prove
useful for treating high-risk patients with the aim to reduce
their risks for COPD.
The aim of this study was to assess the association of
GSTT1, GSTM1, and EPHX1; 113tyrosine/histidine (exon 3)




The study group comprised 146 cases of COPD and 130 appar-
ently healthy controls. All our subjects were Egyptians. They
were all males. Patients with COPD were in the age of 40–67
(56.40 ± 6.40) years. Control subjects were in the age of
30–57 (46.6 ± 6.34) years. All COPD patients were smokers.
60% of control subjects were current smokers. None of the
control subjects had any family history of COPD. COPD
was diagnosed on the basis of history, clinical examination,
radiological examination and pulmonary function tests
(PFT). PFT, such as forced vital capacity (FVC), forced expi-
ratory volume in one second (FEV1), FEV1/FVC ratio and
mid-expiratory ﬂow (FEF25–75%) were performed for all sub-
jects. Any patient with a history of bronchial asthma, diabetes,
hypertension and any other associated primary neoplasm, or
having a history of it was excluded from the study. Routine
laboratory investigations including examination of the sputum
for Gram stain, acid fast bacilli, were carried out. Chest X-ray
was performed for all subjects. Informed consent was obtained
for experimentation with human subjects prior to blood and
data collection. The procedures followed were in accordance
with the ethical standards of the responsible institutional com-
mittee on human experimentation (IRB: 9038329, 01/05/2012)
and with the Helsinki Declaration of 1975, as revised in 1983.
Status of informed consent (IC) is supplied as supplemental
material.
DNA isolation
High molecular weight DNA from peripheral blood of COPD
patients and controls was isolated using DNA puriﬁcation kit
(QIAampDNA Blood Mini Kit, Qiagen, 28159 Avenue
Stanford, Valencia, USA). DNA was quantiﬁed spectrophoto-
metrically at 260 nm and 280 nm and stored at 20 C.
Genotyping assays
Genotyping of the GSTM1 and GSTT1 loci was carried out by
a multiplex PCR reaction on a Perkin Elmer thermal cycler
(Gene amp, PCR system 2400 PERKIN ELMER, version
2.11, USA). The genotypes were analyzed according to the
protocol of Arand et al. [16] Genomic DNA was ampliﬁed
by using 2 sets of primers: GSTM1 (F): 50-GAA CTC CCT
GAA AAG CTA AAG C-30; GSTM1 (R): 50 GTT GGG
CTC AAA TAT ACG GTG G-30; GSTT1 (F): 50-TTC CTT
ACT GGT CCT CAG ATC TC- 30; GSTT1(R): 50-TCA
CCG GAT CAT GGC CAG CA-30. Reaction mixture was
50 lL containing 1 lg DNA, 200 lM dNTPs, 2.5 U Taq poly-
merase (DreamTaq DNA Polymerase, Fermentas Inc. USA,
798 Cromwell Park Drive, Glen Burnie, MD 21061), 0.5 lM of
GSTM1 and 0.3 lM of GSTT1 primers. A total of 40 PCR
cycles with denaturation at 94 C for 1 min, annealing at
59 C for 1 min, and extension at 72 C for 1 min were con-
ducted. An initial DNA denaturation at 95 C and a ﬁnal
GSTM1, GSTT1 and EPHX1 gene polymorphisms and susceptibility to COPD in Egypt 831extension at 72 C were carried out for 5 min each. The PCR
product was then subjected to electrophoresis on a 2% agarose
gel. The presence of bands of 480 and 215 bp was indicative of
the GSTT1 and GSTM1 genotypes respectively, whereas the
absence indicated the null genotype for that gene (Fig. 1A).
This method cannot differentiate between the wild type and
heterozygous state. It determines only homozygous deletion
of GSTM1 and/or GSTT1 genes.
Genotyping of the EPHX1 was performed via two separate
polymerase chain reactions (PCR) used to detect two muta-
tions in the EPHX1 gene [14]. The primer pairs EPO1 (50-G
ATCGATAAGTTCCGTTTCACC-30) and EPO2 (50-ATCC
TTAGTCTTGAAGTGAGGAT-30) were used for exon 3
variants. The primer pairs EPO3 (50-ACATCCACTTCATC
CACGT-30) and EPO4 (50-ATGCCTCTGAGAAGCCAT-30)Figure 1 Agarose gel electrophoresis. (A) GST PCR products
after ampliﬁcation. 8. bp ladder; 5. non-template control; 1,4,6.
both GSTM1 and GSTT1 genotype; 2,7. GSTM1-null; 3. GST
double-null. (B) EPXH1 exon 3 PCR product after digestion. 6. bp
ladder; 1. Tyr/His; 2,4,5. Tyr/ Tyr; 3. His/His. (C) EPXH1 exon 4
PCR product after digestion. 6. bp ladder; 1. Arg/Arg; 2,3,5.
His/His; 4. His/Arg.were used to test mutation in exon 4. PCR was carried out
on Perkin Elmer thermal cycler (Gene amp, PCR system
2400 PERKIN ELMER, version 2.11, USA). Reaction mix-
ture was 25 lL containing 1 lg DNA and 0.3 lM of each
EPO primer. In Go Taq Green Master Mix, 2· (Promega
corporation, USA) consisted of Go Taq DNA Polymerase
supplied in 2· Green Go Taq Reaction Buffer (PH 8.5),
400 lM dNTPs and 3 mM MgCl2. For exon 3, the PCR con-
ditions were as follows: after 5 min of pretreatment at 94 C,
the reaction mixture was subjected to 47 cycles at 94 C for
1 min, at 46 C for 70 s, and at 72 C for 70 s; for exon 4,
the initial pretreatment at 94 C for 5 min was followed by
38 cycles at 94 C for 1 min, at 56 C for 1 min, and at 72 C
for 1 min. Final extension was carried out at 72 C for
10 min. The resulting DNA fragments were digested with
EcoRV (Promega corporation, USA) (exon 3) and RsaI
(Promega corporation, USA) (exon 4) (37 C, overnight).
Non template controls were included every PCR run. The frag-
ments were separated on 4% agarose gel after enzyme diges-
tion. The gels were stained with ethidium bromide and
transilluminated with the UV light. The presence of bands of
140 and 162 bp was indicative of the EPHX1 exon 3 Tyr and
His alleles respectively (Fig. 1B). The presence of bands of
210 and 164 bp was indicative of the EPHX1 exon 4 His and
Arg alleles respectively (Fig. 1C).
Statistical analysis
Demographic data and spirometric parameters are presented
as means ± standard deviation. v2 test was used to compare
the proportions of categorical variables in cases and controls.
The distributions of genotypes for each polymorphic site in the
EPHX1 gene were tested for the Hardy–Weinberg heredity
equilibrium by v2 tests. Odds ratios (OR) and 95% conﬁdence
intervals (CI) were calculated to examine the association
between the GSTM1, GSTT1, and EPHX1 genotypes and
the risk of COPD. The co-dominant, the dominant and the
recessive modes were used. In addition, logistic regression
was used to determine the odds ratios adjusted for potential
confounding factors (age and smoking status). All tests were
performed using Statistical Package for the Social Sciences,
version14.0 (SPSS Inc., Chicago, IL, USA). P< 0.05 was con-
sidered signiﬁcant.
Results
The study included 146 COPD patients in addition to 130 con-
trol subjects. The age, gender, smoking and pulmonary func-
tion tests (PFT) data of our subjects are tabulated in
Table 1. The proportion of smokers was signiﬁcantly lower
(59.2% versus 100%; P< 0.001) in the control group than
in patients with COPD. COPD patients’ PFT parameters
were signiﬁcantly lower in COPD patients than controls
(P< 0.001).
GST genotype distribution
The frequency of GSTM1-null genotype was signiﬁcantly
higher in patients than in controls (72.6% versus 43.8%,
P< 0.001). The frequency of GSTT1 genotypes did not differ
signiﬁcantly between patients and controls (P= 0.4) (Table 2).






















39.64 ± 14.54 13.23 ± 5.67
FVC%* (mean ± SD) 83.08 ± 16.48 89.54 ± 14.3
FEV1%* (mean ± SD) 53.13 ± 15.88 85.56 ± 8.65
FEV1/FVC%* (mean ± SD) 59.95 ± 9.22 87.04 ± 13.76
FEF25–75%* (mean ± SD) 48.95 ± 3.14 90.45 ± 7.67
* P< 0.001.
Table 2 Comparison of GSTM1 and GSTT1 genotype
frequencies in COPD patients and controls (univariate analysis)









Present 40 (27.4%) 73 (56.2%) 1.00 <0.001
Null 106 (72.6%) 57 (43.8%) 1.65 (0.09–3.99)
GSTT1
Present 102 (69.9%) 96 (74.4%) 1.00 0.40
Null 44 (30.15%) 33 (25.6%) 0.73 (0.33–1.62)
Table 3 Combined effects of GSTM1 and GSTT1 null









MM 14 (9.6%) 16 (12.3%) 1.00 –
TT 76 (52.1%) 39 (30.0%) 3.17 (0.78–12.89) 0.05
TM 26 (17.8%) 57 (43.8%) 0.54 (0.18–1.68 0.13
Both null 30 (20.5%) 18 (13.8%) 3.45 (1.07–11.14) 0.17
832 R.A. El Wahsh et al.There was no signiﬁcant difference between COPD patients
and controls regarding carrying GSTT1 gene only, both
GSTT1 and GSTM1 genes or both null GSTT1 and null
GSTM1 genes. Carriers with both null GSTT1 and null
GSTM1 genes were at a higher risk of COPD (OR 3.45,
95% CI = 1.07–11.14) (Table 3)
EPHX1 genotype distribution
The genotype frequencies determined for residue 113 alleles
indicate that this locus may not be in Hardy–Weinbergequilibrium, whereas frequencies observed for residue 139 alle-
les were similar to expected values.
In the co-dominant model, the frequency of exon 3
heterozygous 113Tyr/His genotypes was higher in the COPD
group compared to the control group (24.7% versus 16.9%)
The frequency of exon 3 homozygous 113His/His genotypes
was slightly higher than in the controls (6.8% versus 4.6%);
the difference was statistically non-signiﬁcant (Table 4).
In the dominant model, there was no statistically signiﬁcant
difference between COPD patients and controls regarding
113Tyr/His–13His/His genotypes (Table 4).
In the recessive model, there was no statistically signiﬁcant
difference between COPD patients and controls regarding
113His/His genotypes (Table 4).
In the co-dominant model, the frequency of exon 4
heterozygous 139His/Arg genotypes was lower in the COPD
group compared to the control group (23.3% versus 38.5%)
The frequency of exon 4 homozygous 139Arg/Arg genotypes
was higher than in the controls (8.2% versus 1.5%); the differ-
ence was statistically signiﬁcant (P= 0.015) (Table 4).
In the dominant model, there was no statistically signiﬁcant
difference between COPD patients and controls 139His/Arg–
139Arg/Arg genotypes (Table 4).
In the recessive model, there was statistically signiﬁcant dif-
ference between COPD patients and controls regarding
139Arg/Arg genotypes. Carriers with exon 4 homozygous
139Arg/Arg genotypes were at a higher risk of COPD (OR
11.10, 95% CI = 1.03–119.21, P= 0.015) (Table 4).
EPHX1 allele distribution
The frequency of EPHX1 exon 3 His allele was signiﬁcantly
higher in patients than controls (19.2% versus 12.7%,
P= 0.04). Carriers with exon 3 His allele were at a higher risk
of COPD (OR 1.63, 95% CI = 1.02–2.6, P= 0.04). The fre-
quency of EPHX1 exon 4 Arg allele did not differ signiﬁcantly
between patients and controls (P= 0.88) (Table 5).
EPHX1 haplotype analysis
There was no signiﬁcant difference between COPD patients
and controls regarding different EPHX1 exon 3 and exon 4
haplotype associations (Global haplotype association p-
value = 0.71) (Table 6).
Interaction analysis of EPHX1 genotypes with GST genotypes
There was no signiﬁcant difference between patients and con-
trols regarding interaction between EPHX1 and GSTM1 geno-
types (Interaction p-value = 0.065 for exon 3 and Interaction
p-value = 0.63 for exon 4) (Table 7).
Carriers with both GSTM1-null and homozygous EPHX1
113Tyr/Tyr or heterozygous EPHX1 113Tyr/His genotypes
were at a higher risk of COPD (OR 3.33, 95%
CI = 1.32–8.35 and OR 14.24, 95% CI = 3.02–67.17 respec-
tively) (Table 7).
Carriers with both GSTM1-null and homozygous EPHX1
139His/His or homozygous 139Arg/Arg genotypes were at a
higher risk of COPD (OR 5.58, 95% CI = 2.14–14.52 and
OR 23.17, 95% CI = 1.74–308.46 respectively) (Table 7).
Table 4 Genotype distribution of epoxide hydrolase1 (EPHX1) exon 3 and exon 4 in patients with chronic obstructive pulmonary
disease and healthy controls in a sample of Egyptian population (n= 276, adjusted for age + smoking).
Genotype Patients (N= 146) Controls (N= 130) OR (95% CI) P
Exon 3
Codominant Tyr/Tyr 100 (68.5%) 102 (78.5%) 1.00 0.54
Tyr/His 36 (24.7%) 22 (16.9%) 1.49 (0.63–3.52)
His/His 10 (6.8%) 6 (4.6%) 1.70 (0.41–7.00)
Dominant Tyr/Tyr 100 (68.5%) 102 (78.5%) 1.00 0.28
Tyr/His-His/His 46 (31.5%) 28 (21.5%) 1.54 (0.71–3.35)
Recessive Tyr/Tyr-
Tyr/His
136 (93.2%) 124 (95.4%) 1.00 0.54
His/His 10 (6.8%) 6 (4.6%) 1.54 (0.38–6.28)
Exon 4
Codominant His/His 100 (68.5%) 78 (60%) 1.00 0.015
His/Arg 34 (23.3%) 50 (38.5%) 0.53 (0.24–1.17)
Arg/Arg 12 (8.2%) 2 (1.5%) 9.25 (0.85–100.58)
Dominant His/His 100 (68.5%) 78 (60%) 1.00 0.49
His/Arg-Arg/Arg 46 (31.5%) 52 (40%) 0.77 (0.37–1.61)
Recessive His/His-His/Arg 134 (91.8%) 128 (98.5%) 1.00 0.015
Arg/Arg 12 (8.2%) 2 (1.5%) 11.1 (1.03–119.21)
Table 5 Allele distribution of epoxide hydrolase1 (EPHX1)
exon 3 and exon4 in patients with chronic obstructive










Tyr 236 (80.80%) 227 (87.3%) 1.00 0.04
His 56 (19.2%) 33 (12.7%) 1.63 (1.02–2.6)
Exon 4
His 234 (80.1%) 207 (79.6%) 1.00 0.88
Arg 58 (19.9%) 53 (20.4%) 0.97 (0.64–1.46)
Table 6 Haplotype association of epoxide hydrolase1
(EPHX1) in patients with chronic obstructive pulmonary
disease and healthy controls in a sample of Egyptian popula-
tion (n= 276, adjusted for age + smoking).
Exon3 Exon4 Frequency OR (95% CI) P
Tyr His 0.6668 1.00 –
Tyr Arg 0.1702 1.16 (0.60–2.24) 0.65
His His 0.1303 1.51 (0.70–3.26) 0.3
His Arg 0.0327 1.15 (0.21–6.29) 0.87
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controls regarding interaction between EPHX1 and GSTT1
genotypes (Interaction p-value = 0.93 for exon 3 and
Interaction p-value = 0.64 for exon 4) (Table 8).
Discussion
It is likely that susceptibility to COPD depends on the coinci-
dent actions of several genetic events due to polymorphisms. In
the present study, GSTM1, GSTT1 and EPHX1 genotypeswere analyzed in order to elucidate the association between
the various genotypes and development of COPD.
The difference in frequencies of genotypes might be relevant
to different metabolizing enzyme activities and types of domi-
nant functional enzymes against oxidative stress in different
races [15].
Glutathione S-transferases genes
Glutathione S-transferases (GSTs) are key players to detoxify
various aromatic hydrocarbons found in cigarette smoke. The
proportion of GSTM1-null genotypes was signiﬁcantly higher
in patients with COPD than in controls in an Egyptian popu-
lation, while there was no difference in the frequency of poly-
morphic genotypes of GSTT1. This was matched with Cheng
et al.’s [15] study on Taiwanese population. The frequency of
homozygous GSTM1-null genotype was signiﬁcantly higher
in Indian patients with COPD [17], while there was no signif-
icant difference in the distribution of homozygous null GSTT1.
However, those results were not conﬁrmed in another Indian
study, where GSTT1-null genotypes rather than GSTM1-null
genotypes were associated with the susceptibility to COPD
despite the relatively small sample size [18]. Our study revealed
that carriers with both null GSTT1 and GSTM1 genes were at
a higher risk of COPD (3.45 times). A study conducted in
Dubai demonstrated that carriers with GSTM1-null genotype
had a high risk of developing COPD, especially with both null
GSTT1 and GSTM1 haplotype [19]. However, there was no
association of GSTT1 and GSTM1 polymorphisms with
COPD in the Chinese population of Hong Kong and
Southern China [20]. The null type of GSTM1 shows defective
function in detoxifying the polycyclic aromatic hydrocarbons
of cigarette smoke and promotes cellular and tissue damage
of the lung due to an excess of oxidants and free radicals.
Microsomal epoxide hydrolase gene
Microsomal epoxide hydrolase (EPHX1) plays an important
role in the metabolism of highly reactive epoxide intermediates
Table 7 Epoxide hydrolase1 (EPHX1) and GSTM1 genotypes cross-classiﬁcation interaction table in patients with chronic
obstructive pulmonary disease and healthy controls in a sample of Egyptian population (n= 276, adjusted for age + smoking).
GSTM1-present GSTM1-null P
Patients Controls OR (95% CI) Patients Controls OR (95% CI)
Exon 3
Tyr/Tyr 28 51 1.00 72 51 3.33 (1.32–8.35) 0.065
Tyr/His 10 16 0.70 (0.19–2.54) 26 6 14.24 (3.02–67.17)
His/His 2 6 1.00 (0.13–7.70) 8 0 –
Exon 4
His/His 36 50 1.00 64 28 5.58 (2.14–14.52) 0.63
His/Arg 2 23 0.24 (0.04–1.31) 32 27 2.31 (0.80–6.65)
Arg/Arg 2 0 – 10 2 23.17 (1.74–308.46)
Table 8 Epoxide hydrolase1 (EPHX1) and GSTT1 genotypes cross-classiﬁcation interaction table in patients with chronic obstructive
pulmonary disease and healthy controls in a sample of Egyptian population (n= 276, adjusted for age + smoking).
GSTT1-null GSTT1-present P
Patients Controls OR (95% CI) Patients Controls OR (95% CI)
Exon 3
Tyr/Tyr 36 26 1.00 64 76 1.35 (0.52–3.47) 0.93
Tyr/His 6 6 1.23 (0.22–6.81) 30 16 2.08 (0.64–6.75)
His/His 2 2 2.35 (0.18–31.34) 8 4 2.01 (0.33–12.44)
His/His 32 20 1.00 68 58 1.51 (0.57–4.02) 0.64
His/Arg 6 12 0.48 (0.09–2.64) 28 38 0.78 (0.26–2.34)
Arg/Arg 6 2 4.82 (0.22–103.46) 6 0 –
834 R.A. El Wahsh et al.formed in cigarette smoke. The population was classiﬁed into
fast, normal, slow and very slow groups of EPHX1 pheno-
types, based on reported polymorphisms within the coding
region of EPHX1 genes, tyrosine/ histidine 113 or his-
tidine/arginine 139 [13,14]. In our study, the genotype frequen-
cies determined for residue 113 alleles indicate that this locus
may not be in Hardy–Weinberg equilibrium, whereas frequen-
cies observed for residue 139 alleles were similar to expected
values. The association between the genotypes of EPHX1
and COPD susceptibility varied among different populations.
Regarding residue 113 in exon 3; in the co-dominant, domi-
nant and recessive models, we did not ﬁnd an association
between genotypes of EPHX1 and COPD susceptibility.
Matched with our results regarding EPHX1 113 heterozygote,
meta-analyses by Hu et al., Lee et al. and Li et al. [21–23]
revealed that EPHX1 113 heterozygote versus the EPHX1
113 wild-type homozygote was not signiﬁcantly different.
Regarding EPHX1 113 mutant homozygotes, both Hu et al.
[21] and Lee et al. [22] meta-analyses reported a slightly
increased risk of COPD for EPHX1 113 mutant homozygote.
Hu et al. [21] meta-analysis showed that the EPHX1 113
mutant homozygote was signiﬁcantly associated with an
increased risk of COPD for Asian populations, but not for
Caucasian populations. This was inconsistent with Li et al.
[23] meta-analysis that revealed that the analyses stratiﬁed by
ethnicity showed the signiﬁcant increase in risk with the
EPHX1 113 mutant homozygote existed only in the
Caucasian populations and not in the Asian populations.
However, In the Li et al. [23] meta-analysis, the analysesstratiﬁed by the cigarette smoking status of the controls
showed that the increased risk of COPD was only detected
in the studies with non-smokers as controls. These results con-
trasted with the study by Brøgger et al. [24] in which a reduced
risk of COPD was detected in the EPHX1 113 mutant
homozygotes. COPD is the outcome of genes and environmen-
tal interactions and the pathogeneses are complex and remain
unclear. These discrepancies could be explained by different
ethnic populations used in the various studies, relatively small
sample sizes with Hardy–Weinberg disequilibrium in our
study. Regarding residue 139 in exon 4, in both the co-
dominant and recessive models, we found a signiﬁcant differ-
ence in EPHX1 139 genotypes between COPD patients and
controls. In the recessive model, Carriers with exon 4 homozy-
gous 139Arg/Arg genotypes were at a higher risk of COPD
(limited by the wide 95% CI) (OR 11.10, 95% CI = 1.03–
119.21, P= 0.015). Meta-analyses by Hu et al., Lee et al.
and Li et al. [21–23] revealed that the EPHX1 139 mutant
heterozygote and the EPHX1 139 mutant homozygote geno-
types were both not signiﬁcantly associated with COPD risk.
However, considering the wide 95% CI observed in our reces-
sive model, results cannot be ruled contradictory.
It is known that allele frequencies vary between races.
Smith and Harrison [14] reported ﬁrst that the EPHX1 gene
polymorphism was associated with susceptibility to pulmonary
emphysema. In their study, the mutant allele frequency of exon
3 (His) was found to be higher in patients with pulmonary
emphysema than in the control group. This was matched with
our study regarding susceptibility to COPD (OR 1.63, 95%
GSTM1, GSTT1 and EPHX1 gene polymorphisms and susceptibility to COPD in Egypt 835CI = 1.02–2.6, P= 0.04). However, no signiﬁcant difference
between COPD patients and controls in the mutant allele fre-
quencies of EPHX1 exon 3 or 4 could be demonstrated in two
Japanese studies [25,26], one Korean study [27] and one
Taiwanese study. [15]
We studied the associations of speciﬁc haplotypes of
EPHX1 gene and COPD risk. None of haplotype combina-
tions of exon 3 (Tyr113His) and exon 4 (His139Arg) polymor-
phisms showed modulation of risk for COPD. This was
matched with Matheson et al. [28]
Interaction analysis of EPHX1 genotypes with GST genotypes
Our study identiﬁed an increased risk for the development of
COPD in the carriers of the combined GSTM1-null and
EPHX1 113 wild homozygote (3.33 times) or EPHX1 113
heterozygote (14.24 times) in an Egyptian population. Cheng
et al. [15] reported in a Taiwanese population an increased
odds ratio for COPD when two genotypes of at least one slow
EPHX1 exon 3 allele (His allele) and GSTM1-null were com-
bined. Zˇidzik et al. [29] study identiﬁed an increased risk for
the development of COPD in the carriers of the combined
GSTM1-null and slow EPHX1 exon 3 genotype in the
Slovak population. To our knowledge, we are the ﬁrst to iden-
tify an increased risk for the development of COPD in the car-
riers of the combined GSTM1-null and EPHX1 139 wild
homozygote with absent fast allele (Arg allele) (5.58 times) in
an Egyptian population. These combinations might cause an
obvious enzymatic defect of detoxifying function in the cellular
defense against various toxic substances in tobacco smoke.
Conclusions
In terms of the limitation in the number of subjects examined,
it was found that EPHX1 exon 3 His allele in addition to the
coexistence of genetic variants, including: – Both null GSTT1
and null GSTM1 genes – the presence of one slow mutant
EPHX1 113 allele or the absence of fast mutant EPHX1 139
allele and the GSTM1-null genotypes (to give defective detox-
ifying enzymatic function), were signiﬁcant risk factors in sus-
ceptibility to COPD in the Egyptian population. Larger scale
gene-environment interaction studies regarding COPD suscep-
tibility are required. Screening of smokers for genetic suscepti-
bility to develop COPD should be done.
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